GLP1 Drugs Not Tied to Pregnancy Loss, Birth Defects

Medscape May 7, 2024
Miriam Davis

TOPLINE:

One of the first studies of its kind finds that inadvertent exposure during early pregnancy to glucagon-like peptide 1 receptor agonists (GLP1-RAs) is not associated with major birth defects or pregnancy loss.

METHODOLOGY:

• This study was a multicentre prospective cohort study of three groups of pregnant women who contacted, or whose physician contacted, any of six European or UK Teratology Information Services between 2009 and 2022:
  • The active exposure group (any GLP1-RA drug exposure in the first trimester for diabetes or obesity treatment; n = 168);
  • A diabetes reference group exposed to at least one non-GLP1-RA drug (usually metformin) in early pregnancy (n = 156); and
  • An overweight/obese reference group (n = 163).
• The main...

Today's Sponsors

Today's Sponsor